全文获取类型
收费全文 | 7053篇 |
免费 | 341篇 |
国内免费 | 40篇 |
专业分类
耳鼻咽喉 | 66篇 |
儿科学 | 131篇 |
妇产科学 | 37篇 |
基础医学 | 964篇 |
口腔科学 | 309篇 |
临床医学 | 382篇 |
内科学 | 1609篇 |
皮肤病学 | 187篇 |
神经病学 | 565篇 |
特种医学 | 290篇 |
外科学 | 1314篇 |
综合类 | 28篇 |
一般理论 | 1篇 |
预防医学 | 226篇 |
眼科学 | 92篇 |
药学 | 355篇 |
中国医学 | 16篇 |
肿瘤学 | 862篇 |
出版年
2023年 | 37篇 |
2022年 | 87篇 |
2021年 | 129篇 |
2020年 | 61篇 |
2019年 | 80篇 |
2018年 | 138篇 |
2017年 | 117篇 |
2016年 | 145篇 |
2015年 | 140篇 |
2014年 | 177篇 |
2013年 | 227篇 |
2012年 | 311篇 |
2011年 | 351篇 |
2010年 | 218篇 |
2009年 | 188篇 |
2008年 | 309篇 |
2007年 | 353篇 |
2006年 | 351篇 |
2005年 | 319篇 |
2004年 | 318篇 |
2003年 | 286篇 |
2002年 | 292篇 |
2001年 | 266篇 |
2000年 | 247篇 |
1999年 | 211篇 |
1998年 | 92篇 |
1997年 | 48篇 |
1996年 | 48篇 |
1995年 | 50篇 |
1994年 | 36篇 |
1993年 | 48篇 |
1992年 | 144篇 |
1991年 | 126篇 |
1990年 | 126篇 |
1989年 | 132篇 |
1988年 | 104篇 |
1987年 | 111篇 |
1986年 | 98篇 |
1985年 | 90篇 |
1984年 | 87篇 |
1983年 | 70篇 |
1979年 | 76篇 |
1978年 | 40篇 |
1977年 | 34篇 |
1973年 | 40篇 |
1971年 | 34篇 |
1970年 | 38篇 |
1969年 | 41篇 |
1968年 | 41篇 |
1967年 | 48篇 |
排序方式: 共有7434条查询结果,搜索用时 15 毫秒
111.
R Nakagawa K Motoki H Nakamura H Ueno R Iijima A Yamauchi S Tsuyuki T Inamoto Y Koezuka 《Oncology research》1998,10(11-12):561-568
Liver metastasis of primary tumor is a clinically major problem. KRN7000, an alpha-galactosylceramide, significantly augments natural killer (NK) activity of spleen cells and shows strong antitumor activity in mice with lung metastasis of melanoma B16 cells. To test whether KRN7000 has an antitumor activity in mice with hepatic metastasis of tumors, we examined the effect of KRN7000 on NK activity of hepatic mononuclear cells (MNC) and the antitumor activity in mice with liver metastasis of EL-4 cells. The in vivo administration of KRN7000 significantly augmented NK activity of hepatic MNC and inhibited tumor growth of EL-4 cells in the liver more markedly than chemotherapeutic agents, leading to a relatively high rate of cured mice. In addition, it appeared that the KRN7000 treatment is effective in mice with established EL-4 tumors. Moreover, we found that KRN7000 can produce significant amounts of interleukin 2 (IL-2), IL-4, IL-12, and interferon-gamma in a dose-dependent manner. These results suggest that KRN7000 will be useful for the treatment of cancer liver metastasis. 相似文献
112.
Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study 总被引:18,自引:0,他引:18
Mulnard RA Cotman CW Kawas C van Dyck CH Sano M Doody R Koss E Pfeiffer E Jin S Gamst A Grundman M Thomas R Thal LJ 《JAMA》2000,283(8):1007-1015
CONTEXT: Several reports from small clinical trials have suggested that estrogen replacement therapy may be useful for the treatment of Alzheimer disease (AD) in women. OBJECTIVE: To determine whether estrogen replacement therapy affects global, cognitive, or functional decline in women with mild to moderate AD. DESIGN: The Alzheimer's Disease Cooperative Study, a randomized, double-blind, placebo-controlled clinical trial conducted between October 1995 and January 1999. SETTING: Thirty-two study sites in the United States. PARTICIPANTS: A total of 120 women with mild to moderate AD and a Mini-Mental State Examination score between 12 and 28 who had had a hysterectomy. INTERVENTIONS: Participants were randomized to estrogen, 0.625 mg/d (n = 42), or 1.25 mg/d (n = 39), or to identically appearing placebo (n = 39). One subject withdrew after randomization but before receiving medication; 97 subjects completed the trial. MAIN OUTCOME MEASURES: The primary outcome measure was change on the Clinical Global Impression of Change (CGIC) 7-point scale, analyzed by intent to treat; secondary outcome measures included other global measures as well as measures of mood, specific cognitive domains (memory, attention, and language), motor function, and activities of daily living; compared by the combined estrogen groups vs the placebo group at 2, 6, 12, and 15 months of follow-up. RESULTS: The CGIC score for estrogen vs placebo was 5.1 vs 5.0 (P = .43); 80% of participants taking estrogen vs 74% of participants taking placebo worsened (P = .48). Secondary outcome measures also showed no significant differences, with the exception of the Clinical Dementia Rating Scale, which suggested worsening among patients taking estrogen (mean posttreatment change in score for estrogen, 0.5 vs 0.2 for placebo; P = .01). CONCLUSIONS: Estrogen replacement therapy for 1 year did not slow disease progression nor did it improve global, cognitive, or functional outcomes in women with mild to moderate AD. The study does not support the role of estrogen for the treatment of this disease. The potential role of estrogen in the prevention of AD, however, requires further research. 相似文献
113.
作者报道1例患原发性气管雪旺细胞瘤(神经鞘瘤)的9岁女患儿合并气道梗阻。CT扫描发现气管内多息肉样肿块,73%的管腔发生梗阻。行气管部分切除及吻合术。病检确诊为起源于雪旺细胞的良性神经源性肿瘤。9岁女患儿的原发性气管雪旺细胞瘤(神经鞘瘤)@Nio M.
@Sano N.
@Kotera 相似文献
114.
A new simply and effective fractionation method for cylindrospermopsin (CYN) analyses was developed. The extract from cells of Cylindrospermopsis raciborskii was resuspended with 0.1 M carbonate buffer at pH 10.5, and pass through the double-cartridges column which was consisted of a styrene polymer cartridge and an anion exchange cartridge. CYN and deoxy-CYN were adsorbed with the anion exchange cartridge. After separation of the anion exchange cartridge, adsorbed compounds were eluted from the cartridge with 50% methanol containing 1% formic acid solution. CYN and deoxy-CYN were selectively condensed in the eluted solution. When CYN was analyzed by LC-photodiode array or LC/MS, only two peaks of CYN and deoxy-CYN were detected quantitatively. The results suggest that the fractionation method is a useful method for CYN analyses and must be utilized for CYN purification. 相似文献
115.
Takeshi Yoshida Go Suzuki Masashi Nibuya Shin-ya Sano Soichiro Nomura 《Nihon shinkei seishin yakurigaku zasshi》2004,24(1):29-31
Although still controversial, iron deficiency has been indicated as one of the risk factors for developing neuroleptic-induced extrapyramidal symptoms (EPSs), including akathisia, dystonia, and neuroleptic malignant syndrome. Here we report our experience of iron supplementation and alternating neuroleptics for treating Parkinsonism in a schizophrenic female patient having severe iron deficient anemia. 相似文献
116.
Motoki Miyazawa Ryuji Ohsawa Takuya Tsunoda Seiko Hirono Manabu Kawai Masaji Tani Yusuke Nakamura Hiroki Yamaue 《Cancer science》2010,101(2):433-439
Vascular endothelial growth factor receptor 2 (VEGFR2) is an essential factor in tumor angiogenesis and in the growth of pancreatic cancer. Immunotherapy using epitope peptide for VEGFR2 (VEGFR2‐169) that we identified previously is expected to improve the clinical outcome. Therefore, a phase I clinical trial combining of VEGFR2‐169 with gemcitabine was conducted for patients with advanced pancreatic cancer. Patients with metastatic and unresectable pancreatic cancer were eligible for the trial. Gemcitabine was administered at a dose of 1000 mg/m2 on days 1, 8, and 15 in a 28‐day cycle. The VEGFR2‐169 peptide was subcutaneously injected weekly in a dose‐escalation manner (doses of 0.5, 1, and 2 mg/body, six patients/one cohort). Safety and immunological parameters were assessed. No severe adverse effect of grade 4 or higher was observed. Of the 18 patients who completed at least one course of the treatment, 15 (83%) developed immunological reactions at the injection sites. Specific cytotoxic T lymphocytes (CTL) reacting to the VEGFR2‐169 peptide were induced in 11 (61%) of the 18 patients. The disease control rate was 67%, and the median overall survival time was 8.7 months. This combination therapy for pancreatic cancer patients was tolerable at all doses. Peptide‐specific CTL could be induced by the VEGFR2‐169 peptide vaccine at a high rate, even in combination with gemcitabine. From an immunological point of view, the optimal dose for further clinical trials might be 2 mg/body or higher. This trial was registered with ClinicalTrial.gov (no. NCT 00622622). (Cancer Sci 2009) 相似文献
117.
Hiroyasu Yasuda Katsutoshi Nakayama Mika Watanabe Satoshi Suzuki Hiromi Fuji Shoji Okinaga Akio Kanda Kiyoshi Zayasu Takahiko Sasaki Masanori Asada Tomoko Suzuki Motoki Yoshida Shinsuke Yamanda Daisuke Inoue Tomohiro Kaneta Takashi Kondo Yoshihiro Takai Hidetada Sasaki Kazuhiro Yanagihara Mutsuo Yamaya 《Clinical cancer research》2006,12(22):6748-6757
PURPOSE: Nitroglycerin may improve the response to chemotherapy in advanced non-small cell lung cancer. The effects and mechanisms of nitroglycerin on the enhancement of chemosensitivity to docetaxel and carboplatin regimen (DCb) in patients with lung adenocarcinoma have not been reported. EXPERIMENTAL DESIGN: Seventeen patients with operable lung adenocarcinoma and stable angina pectoris were selected to investigate the effects of nitroglycerin on immunoreactivity for hypoxia-inducible factor 1alpha (HIF-1alpha), vascular endothelial growth factor (VEGF), P-glycoprotein (P-gp), the production of which is regulated by HIF-1, and p53 proteins in their resected tumor by semiquantitative immunohistochemical analyses. Eight of 17 patients were treated with nitroglycerin patches before operation, but 9 of 17 patients were not. Furthermore, to study the relationship between changes in plasma VEGF levels by nitroglycerin treatment and response to DCb, 29 patients with advanced lung adenocarcinoma were treated with nitroglycerin for 3 days before chemotherapy using DCb. RESULTS: The rates of immunoreactive cells for HIF-1alpha, VEGF, and P-gp in tumor tissues treated with nitroglycerin were lower than those without nitroglycerin, but those for p53 were not different between those treated with and without nitroglycerin. Furthermore, the rates of immunoreactive cells for VEGF and P-gp proteins were significantly associated with those for HIF-1alpha in tumor tissue. The magnitude of decrease in plasma VEGF levels after treatment with nitroglycerin was significantly associated with response to DCb in patients with advanced lung adenocarcinoma. CONCLUSIONS: Nitroglycerin treatment may improve response to DCb in patients with lung adenocarcinoma, partly through decreasing VEGF and P-gp production via reduction of HIF-1alpha. 相似文献
118.
Kazumasa Miki Masao Ichinose Norio Kawamura Masashi Matsushima Haron Bin Ahmad Masayoshi Kimura Junjiro Sano Takao Tashiro Nobuyuki Kakei Hiroshi Oka Chie Furihata Kenji Takahashi 《Cancer science》1989,80(2):111-114
Serum pepsinogen levels were measured in 137 stomach cancer patients and compared with those of 288 normal cancer-free subjects. The serum pepsinogen levels of stomach cancer patients, especially pepsinogen I and the pepsinogen I/pepsinogen II ratio were significantly lower than those of normal controls and correlated well with the extent of chronic gastritis associated with the cancerous stomach. These results were in good accordance with the results of previous studies indicating that the cancer derived from the stomach where chronic gastritis/intestinal metaplasia is extensive. The high sensitivity and specificity of this non-invasive serum test to detect chronic gastritis suggested the possibility of its application to the mass screening of stomach cancer. 相似文献
119.
Hye Seong Ahn MD Hyuk‐Joon Lee MD Seokyung Hahn PhD Woo‐Ho Kim MD Kuhn Uk Lee MD Takeshi Sano MD Stephen B Edge MD Han‐Kwang Yang MD 《Cancer》2010,116(24):5592-5598
BACKGROUND:
The seventh TNM staging system for gastric cancer of the American Joint Committee on Cancer/International Union Against Cancer (AJCC/UICC) had a more detailed classification than the sixth TNM staging system for both the tumor (T) and lymph nodes (N). The authors compared survival rates assessed by the seventh staging system with those by the sixth system.METHODS:
The authors analyzed the prospectively collected database on patients with gastric cancer who underwent surgery at Seoul National University Hospital between 1986 and 2006, and calculated the survival rates of 9998 cases with primary cancer, R0 resection, and >14 retrieved lymph nodes.RESULTS:
The 5‐year cumulative survival rates (5YSR) according to the seventh edition T or N classifications were significantly different. The 5YSR according to seventh edition of the TNM staging system were 95.1% (stage IA), 88.4% (stage IB), 84.0% (stage IIA), 71.7% (stage IIB), 58.4% (stage IIIA), 41.3% (stage IIIB), and 26.1% (stage IIIC), which were significantly different from each other. The 5YSR of the seventh edition T2 and T3 classifications had significant differences in patients with every N classification, and the 5YSR of seventh edition N1 and N2 classifications had significant differences in T2 patients, T3 patients, and T4 patients. Each stage in the sixth edition was divided into the seventh edition stage with different survival rates. In addition, the number of homogenous groupings in seventh edition TNM stages was increased from 1 to 2.CONCLUSIONS:
The seventh system provided a more detailed classification of prognosis than the sixth system, especially between T2 and T3 tumors and N1 and N2 tumors, although further studies were found to be needed for the N3a and N3b classification. Cancer 2010. © 2010 American Cancer Society. 相似文献120.
Akira Horikawa Yuji Kasukawa Michio Hongo Hiroyuki Kodama Akihisa Sano Naohisa Miyakoshi 《Medicine》2022,101(43)
Although osteoporotic patients have already been recognized as having a low-volume vitamin D status, the concentration of active vitamin D precursor has not been studied in detail. This trial aimed to clarify the concentration of 25-hydroxyvitamin D (25-OHD), which is a natural type of vitamin D and compare between 2 separate areas in Japan. To compare and clarify the concentration of 25-OHD between 2 separate areas, Japanese patients who were diagnosed as having osteoporosis based on bone mineral density were studied. We analyzed 2 different hospitals’ patients whose residence is separated into a northern district (Akita city: north latitude 39” 43’) and a southern district (Shizuoka city: north latitude 34” 58’). Both of them have completely different daylight hours. Three-hundred sixty eight patients (174 in Akita, 194 in Shizuoka) were enrolled in this trial to compare the differences of concentration of 25-OHD by Welch’s t t-test. There were significant differences in the concentration of 25-OHD and age between them. Akita patients were significantly higher than that of Shizuoka patients despite Shizuoka having much daylight hours of Akita. In conclusion, there might be no relationship between the concentration of 25 OHD and exposure to sunlight. 相似文献